Actualités sur Medicale

12.06.2016 – 16:16
Novo Nordisk
Semaglutide Demonstrated Superior Improvements in Glycaemic Control vs Sitagliptin (SUSTAIN 2) and Exenatide ER (SUSTAIN 3) in Two Clinical Trials in Adults With Type 2 Diabetes
New Orleans (ots/PRNewswire) - This material is intended for global medical media only. For journalistic assessment and preparation before publication. Abstracts 185-OR and 187-OR Findings from two phase 3a clinical trials for semaglutide, an investigational glucagon-like peptide-1 (GLP-1) analogue, were presented ...
plus
11.06.2016 – 17:01
sanofi-aventis Group
Successful Switch to Sanofi's Toujeo® Evaluated in a Real-World Setting
Paris (ots/PRNewswire) - Sanofi announced today the release of the new real world data assessing the use of Toujeo® (insulin glargine injection 300 Units/mL). The U.S. Predictive Health Intelligence Environment (PHIE) database, containing a substantial amount of patient level information, was analyzed to assess Toujeo in this real life setting. The study examined ...
plus
11.06.2016 – 17:01
Novo Nordisk
Tresiba® (insulin degludec injection U-100) demonstrated significantly lower rates of overall, nocturnal and severe hypoglycaemia vs insulin glargine U-100
New Orleans (ots/PRNewswire) - This material is intended for global medical media only. For journalistic assessment and preparation before publication. Abstracts 87-LB and 90-LB New findings from the two phase 3b SWITCH trials showed that treatment with long-acting basal insulin Tresiba® (insulin degludec injection ...
plus
10.06.2016 – 21:13
Shire Pharmaceuticals Group Plc
Shire Announces Completion of Decentralized Procedure in Europe for Immunoglobulin Treatment Cuvitru
Zug, Switzerland (ots/PRNewswire) - - Cuvitru (IG 20mg/ml solution for subcutaneous injection) builds on company's broad portfolio of IG treatments gained through combination with Baxalta - New option to treat primary and certain secondary immunodeficiencies can help meet patient needs related to number of infusion ...
plus
10.06.2016 – 15:18
ViiV Healthcare
ViiV Healthcare Announces FDA Approval to Lower the Weight Limit for dolutegravir in Children and Adolescents Living With HIV
London (ots/PRNewswire) - Reduction of weight limit to at least 30kg means more children and adolescents will be eligible for dolutegravir ViiV Healthcare today announced that the US Food and Drug Administration (FDA) has approved a supplemental New Drug Application (sNDA) for dolutegravir 10mg and 25mg oral ...
plus
10.06.2016 – 07:01
UCB Pharma
UCB's bimekizumab demonstrates positive results in early development in patients with psoriatic arthritis
Brussels (ots/PRNewswire) - - Bimekizumab is a highly selective monoclonal antibody that inhibits the activity of both IL-17A and IL-17F, key pro-inflammatory cytokines expressed in several inflammatory diseases[1],[2] - In this early proof of concept study, bimekizumab showed fast and sustained efficacy on disease ...
plus

08.06.2016 – 00:02
UCB Pharma
UCB Commitment to Addressing Real World Patient Needs on Display at the Annual European Congress of Rheumatology (EULAR 2016)
Brussels (ots/PRNewswire) - For medical and trade media only. New data highlight breadth of UCB's pioneering portfolio with four molecules across five indications: - An oral presentation of data from the two year C-EARLY(TM) Phase 3 study of Cimzia®, exploring different dosing strategies - Oral presentations from ...
plus
07.06.2016 – 17:17
Debiopharm International SA
Debiopharm International SA Initiates Clinical Phase II Study Evaluating Debio 1143 in Ovarian Cancer
Lausanne, Switzerland (ots/PRNewswire) - Debiopharm today announced the start of a phase II clinical trial for Debio 1143 in combination with standard of care Carboplatin and Paclitaxel in Epithelial Ovarian Cancer Debiopharm International SA (Debiopharm), part of Debiopharm Group(TM), a Swiss-based global ...
plus
06.06.2016 – 13:36
Novo Nordisk
Novo Nordisk to Present 53 Abstracts at 76th Annual American Diabetes Association Scientific Sessions in New Orleans, LA
Bagsværd, Denmark (ots/PRNewswire) - This material is intended for global medical media only. For journalistic assessment and preparation before publication. Novo Nordisk, a global leader in diabetes care, today announced that data from 53 abstracts including 8 oral presentations will be shared at the upcoming 76th ...
plus
06.06.2016 – 06:00
JSS Medical Research Inc.
JSS Medical Research Establishes Its Presence in Europe
Montreal (ots/PRNewswire) - - JSS Medical Research, an international contract research organization active in over 20 countries acquires Bonne Santé in Poland as catalyst for European expansion JSS Medical Research Inc., an International Contract Research Organization (CRO) with offices in Canada, Latin America and Asia/Pacific, announced the acquisition of Bonne Santé, a Polish CRO, to accelerate the expansion into ...
plus
04.06.2016 – 15:09
Merck Healthcare Germany
Merck Partners with Array BioPharma and Pierre Fabre to Initiate BRAF-mutant CRC Phase III Trial
Darmstadt, Germany (ots/PRNewswire) - Not intended for UK- or US-based media - BEACON CRC trial will assess efficacy of combination regime Erbitux® (cetuximab), binimetinib and encorafenib in BRAF-mutant metastatic colorectal cancer (mCRC) Merck, a leading science and technology company, jointly announced with ...
plus
02.06.2016 – 18:01
Novo Nordisk
Three-year Data Show Early Response to Saxenda® Resulted in Improvements in Weight Loss and Cardiometabolic Risk Factors
Gothenburg, Sweden (ots/PRNewswire) - This material is intended for global medical media only. For journalistic assessment and preparation before publication. Poster# PP3.09 Today, data from a post hoc analysis of the three-year part of the phase 3a SCALE(TM) (Satiety and Clinical Adiposity - Liraglutide Evidence) ...
plus

02.06.2016 – 14:03
Isofol Medical AB
Isofol Medical Has Successfully Advanced to the Next Dose Level of Modufolin® in a Phase I/II Clinical Trial in Colorectal Cancer
Gothenburg, Sweden (ots/PRNewswire) - Isofol Medical AB today announced initiation of the next dose level of Modufolin®, in combination with 5-FU and oxaliplatin or 5-FU and irinotecan, in the ongoing, incremental dose cohort, phase I/II clinical trial, ISO-CC-005. In total 16 patients with stage IV colorectal ...
plus
02.06.2016 – 09:02
Debiopharm International SA
FDA Grants Orphan Drug Designation to Debiopharm International SA's IAP Inhibitor Debio 1143 in the Treatment of Ovarian Cancer
Lausanne, Switzerland (ots/PRNewswire) - Debiopharm International SA (Debiopharm), a Swiss-based company, part of Debiopharm Group(TM), today announced that the FDA Office of Orphan Products Development (OOPD) has granted Orphan Drug Designation to Debio 1143 for treatment of ovarian cancer. Orphan Drug Designation ...
plus
31.05.2016 – 15:02
ViiV Healthcare and the International Association of Providers of AIDS Care (IAPAC)
ViiV Healthcare and the International Association of Providers of AIDS Care (IAPAC) to Collaborate on Fast-Track Cities
London and Washington (ots/PRNewswire) - Collaboration will focus on 16 cities where HIV is highly prevalent and will help monitor progress towards the attainment of UNAIDS 90-90-90 and zero discrimination and stigma targets ViiV Healthcare and the International Association of Providers of AIDS Care (IAPAC) today ...
plus
30.05.2016 – 19:01
Teva Pharmaceutical Industries Ltd.
Teva Achieves Positive Conclusion for the European Decentralised Procedure (DCP) for BRALTUS® (tiotropium bromide)
Amsterdam (ots/PRNewswire) - Positive conclusion of a European DCP for approval of a tiotropium bromide-based maintenance treatment for those people living with COPD in a new inhaler (Zonda®) Teva Pharmaceutical Industries Ltd., announced today that it has received a positive conclusion of a DCP for BRALTUS® ...
plus
28.05.2016 – 00:16
Novo Nordisk
Semaglutide Demonstrated Superior Glycaemic Control vs Insulin Glargine U100 in Adults with Type 2 Diabetes
Orlando, Florida (ots/PRNewswire) - This material is intended for global medical media only. For journalistic assessment and preparation before publication. Abstract #290 Findings from a phase 3a clinical trial for semaglutide, an investigational glucagon-like peptide-1 (GLP-1) analogue, demonstrated that treatment ...
plus
27.05.2016 – 08:01
Shire Pharmaceuticals Group Plc
Shire Receives Positive CHMP Opinion in Europe for Revestive® (Teduglutide) for Paediatric Patients with Short Bowel Syndrome
Zug, Switzerland (ots/PRNewswire) - Shire plc (LSE: SHP, NASDAQ: SHPG) today announced that the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion, recommending the extension of the approval of Revestive[®*] (teduglutide) 5 mg powder and solvent for ...
plus

26.05.2016 – 10:10
RB and PAGB
Elevating Role of Self-Care and Improving Regulatory Environment Could Relieve Pressure on Healthcare Systems Worldwide
London (ots/PRNewswire) - For medical trade media only - A white paper written by the Economist Intelligence Unit reports that improved regulatory harmonisation may support patient empowerment and self-care, and finds that the issue is not receiving enough attention - Self-care and improved access to consumer health ...
plus
25.05.2016 – 08:46
Merck Healthcare Germany
Merck to Present Data on Rebif® (interferon beta-1a) and Cladribine Tablets for Multiple Sclerosis at 2nd Congress of the European Academy of Neurology
Darmstadt, Germany (ots/PRNewswire) - Merck, a leading science and technology company, today announced that clinical data on Rebif® (interferon beta-1a), the company's high-dose, high-frequency interferon beta for relapsing forms of multiple sclerosis, and Cladribine Tablets, an investigational, oral, small ...
plus
24.05.2016 – 14:03
Isofol Medical AB
Isofol Announces Successful Meetings With European and US Regulatory Authorities Regarding the Design of a Pivotal Phase II Clinical Trial of Isofol's Lead Drug Candidate, Modufolin®
Gothenburg, Sweden (ots/PRNewswire) - Isofol Medical AB, a clinical stage pharmaceutical company, developing novel products for unmet needs within oncology is pleased with the outcome of these meetings and will initiate preparations for a pivotal Phase II/III clinical trial in colorectal cancer. This presents the ...
plus
18.05.2016 – 23:16
Merck Healthcare Germany
Bringing Innovation to Patients: Merck Presents New Advances at ASCO 2016
Darmstadt, Germany (ots/PRNewswire) - Not intended for UK- or US-based media ASCO Abstract # Avelumab: 4009, TPS4134, TPS4135, 9036, TPS9105, 3055, TPS3106, 8503, 4514, 4516, 5533, TPS5600, TPS4580, 9508; tepotinib: 4072 - Abstracts featuring Merck compounds span a broad range of cancers, with an emphasis on those which are difficult-to-treat and represent ...
plus
04.05.2016 – 18:38
Teva Pharmaceuticals Europe BV
Teva Breathes Its Way to a Guinness World Records Title
Amsterdam (ots/PRNewswire) - What can you do in 30 minutes? Catch up on your favourite sitcom? Burn 180 calories on an exercise bike? Clean the bathroom? Or break a Guinness World Records(TM) title? (Logo: http://photos.prnewswire.com/prnh/20160504/363641LOGO ) (Photo: http://photos.prnewswire.com/prnh/20160504/363642 ) That is what over 600 employees from Teva have done. Taking a break from their day jobs in areas such ...
plus
28.04.2016 – 09:01
Accuray Europe
Accuray to Unveil Latest Innovations at Estro
Sunnyvale, California (ots/PRNewswire) - Next generation delivery system designed for increased throughput, higher reliability and ease of serviceability Accuray Incorporated (NASDAQ: ARAY) announced the company will showcase its portfolio of radiation therapy delivery systems and software solutions at the annual European Society for Therapeutic Radiology and Oncology (ESTRO) meeting being held in Turin, Italy April 29 - ...
plus

25.04.2016 – 08:13
Merck Healthcare Germany
Phase III TAILOR Landmark Study Demonstrates Significant Benefits of Erbitux in Combination with FOLFOX Over FOLFOX Alone
Darmstadt, Germany (ots/PRNewswire) - Not intended for UK- or US-based media - Chinese pivotal Phase III study meets its primary endpoint of increased progression-free survival in first-line treatment of patients with RAS wild-type metastatic colorectal cancer - Merck will work with relevant authorities to make ...
plus
19.04.2016 – 17:01
EBOVAC1
Global Public-Private Partnership Announces Publication of Positive Phase 1 Data for Ebola Vaccine Regimen in JAMA
London (ots/PRNewswire) - First published clinical data show prime-boost Ebola vaccine regimen produced an antibody response in 100 percent of healthy volunteers that was sustained 8 months following immunization An Ebola vaccine is still urgently needed to address the problem of Ebola persistence in affected ...
plus
18.04.2016 – 16:20
Shire Pharmaceuticals Group Plc
Shire plc ("Shire") Publication of Circular, Notice of General Meeting and Prospectus and Directorate Change
Dublin (ots/PRNewswire) - NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART, IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OF THAT JURISDICTION. PLEASE SEE THE IMPORTANT NOTICE WITHIN THIS ANNOUNCEMENT. Publication of Circular, Notice and Prospectus ...
plus
17.04.2016 – 08:01
Novo Nordisk
Novo Nordisk mark World Haemophilia Day and unveil the 2016 HERO Research Grant
Zürich, Switzerland (ots/PRNewswire) - This material is intended for global medical media only. For journalistic assessment and preparation before publication. Today, on World Haemophilia Day, Novo Nordisk announces that the grant scheme to support and encourage research projects focused on the psychosocial issues faced by people with haemophilia is open for ...
plus
15.04.2016 – 09:01
Debiopharm International SA
Debiopharm International SA Announces Presentation at AACR of Non-clinical Data Relating to its Targeted Investigational Compound Debio 1347/CH5183284, a Selective FGFR 1,2,3 Inhibitor
Lausanne, Switzerland (ots/PRNewswire) - Debiopharm International SA (Debiopharm), a Swiss-based company, part of Debiopharm Group(TM), today announces that non-clinical data on the clinical-stage investigational compound Debio 1347/CH5183284 (FGFR 1,2,3 inhibitor) will be presented at the 2016 Annual Meeting of the ...
plus
13.04.2016 – 17:39
Qiagen N.V.
QIAGEN Posts 2015 Annual Report on Its Website
Venlo, The Netherlands (ots/PRNewswire) - QIAGEN N.V. (Nasdaq:QGEN) (Frankfurt:QIA) has posted its 2015 Annual Report on its website at http://www.qiagen.com/About-Us/Investors/Financial-Information/Financial-Reports QIAGEN's Annual Report on Form 20-F for the year ended December 31, 2015 has been filed with the U.S. Securities and Exchange Commission (SEC) on February 26, 2016, a copy of which can be found on the website ...
plus

Précédent34353637383940414243Suivant